Danaher said operating profit margin for Q3 2025 was 19.1%, up 260 basis points from 16.5% in the comparable prior-year period, while the 9-month year-to-date operating profit margin was 18.0%, down 180 basis points from 19.8% in the comparable prior-year period.

1. 01

   Danaher said operating profit margin for Q3 2025 was 19.1%, up 260 basis points from 16.5% in the comparable prior-year period, while the 9-month year-to-date operating profit margin was 18.0%, down 180 basis points from 19.8% in the comparable prior-year period.

2. 02

   The company said that in the Q3 comparison, prior-year trade name impairment charges (net of Q3 2025 impairment charges) had a favorable impact of 220 basis points, and in the 9-month comparison, 2025 impairment charges (net of prior-year trade name impairment charges) had an unfavorable impact of 180 basis points.

3. 03

   The company said Biotechnology segment total sales increased 9.0% in Q3 and 7.5% in the 9-month period, with consumables sales leading the increase. Operating profit margin in Q3 declined 400 basis points, and the company cited an unfavorable impact of 475 basis points from impairment charges related to technology and other intangible assets.

4. 04

   Danaher said operating cash flow for the 9-month period in 2025 was approximately $4.3 billion, down $370 million or 8% from the comparable prior-year period. The company cited a decrease in net income of $396 million as a factor.

Key figures

Quarter ended September 26, 2025

Revenue

$6.1B

Operating income

$1.2B

Net income

$908M

EPS

$1.27

Gross profit

$3.5B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.